Browse Articles
Discover research articles across all indexed journals
Safety and efficacy of immune checkpoint inhibitor rechallenge in metastatic fumarate hydratase-deficient renal cell carcinoma: A retrospective study.
500 Background: Fumarate hydratase–deficient renal cell carcinoma (FH-deficient RCC) is a rare subtype of kidney cancer characterized by FH-inactivating alterations. Studies have revealed highly immunogenic features in this lethal disease, providing molecular evidence for implement of immune checkpoint inhibitor (ICI). Due to the lethal nature of FH-deficient RCC, a significant proportion of patients continue to have disease progression after receiving ICI combination therapy (ICI plus tyrosine kinase inhibitors, TKI). Herein, we aim to evaluate the safety and efficacy of immune checkpoint inhibitor rechallenge in metastatic fumarate hydratase-deficient renal cell carcinoma in real-world settings. Methods: A multicenter database of patients diagnosed with FH-deficient RCC, identified through IHC evidence of negative FH and/or positive 2SC, was explored. The study enrolled patients with metastatic FH-deficient RCC who received ICI combination therapy within three months of discontinuing prior ICI treatments between January 2018 and July 2023. Results: A total of 18 patients, each receiving at least two lines of ICI combination therapy, were included in the study. The majority of patients (n=15) experienced disease progression following prior-line immunotherapy. Among these, with 66.7% (10/15) showed progression in the original lesions, while 33.3% (5/15) developed new metastatic lesions. Three patients transitioned to later-line immunotherapy due to immune-related adverse events (irAEs) of grade 3 or higher. The incidence of grade 1-2 irAEs was comparable between prior and later-line therapies (28.15% vs. 27.30%, p=0.8932), as was the incidence of grade 3 or higher irAEs (0.86% vs. 0.29%, p=0.594). For the entire cohort, the median progression-free survival (mPFS) for prior-line ICI combination therapy was 16.2 months (95% CI: 5.565-26.835 months), and the mPFS for later-line ICI combination therapy was 15.2 months (95% CI: 3.915-26.485 months). The objective response rate (ORR) and disease control rate (DCR) for later-line therapy were 17% and 78%, respectively, compared to an ORR of 28% and a DCR of 67% for prior-line therapy. Conclusions: This cohort study demonstrated that ICI rechallenge achieved mPFS of 15.2 months and DCR of 78%, with a favorable safety profile in patients with FH-deficient RCC. Therefore, the resumption of ICI combination therapy may be a viable option for managing this lethal subtype of RCC.
Correction: Health and wellness in the Australian coal mining industry: An analysis of pre-post findings from the RESHAPE workplace health promotion program
Understanding in same- versus cross-race close relationships predicts the well-being of people of color over time
First line treatment of pancreatic metastases in metastatic renal cell carcinoma: Insights from the UK Renal Oncology Collaborative (UK ROC)—Tyrosine kinase inhibitors time to shine?
514 Background: Pancreatic metastases (PM) are a rare site of spread in metastatic renal cell carcinoma (mRCC). It has been suggested that patients with PM have improved survival outcomes and more angiogenic driven biology than other metastatic sites. We sought to define these outcomes and determine if TKI based combination is the preferred option in the first line treatment approach. Methods: UK ROC is a RWE multicentre study from patients starting SACT for mRCC in 17 UK centres. Retrospective analysis of patients with and without PM was performed. Survival data were compared using Kaplan–Meier curves, and the statistical significance of differences in outcome between the groups was assessed with the log‐rank test. Progression-free survival (PFS) and Overall Survival (OS) from the start of first-line therapy and initial diagnosis was assessed using Cox regression analysis comparing single agent TKI, IO/TKI and IO/IO combinations. Results: 1319 patients were identified, median age of 65. 90 (6.8%) patients within the cohort had PM. Of these 90, 11 patients had pancreatic only metastatic disease. There were no statistical differences in the distribution of the IMDC prognostic group (p=0.194), type of first-line treatment (IO/IO, TKI or TKI/IO) (p=0.189) or age (p=0.079) in patients with and without PM. Interestingly there was a significantly greater proportion of females in the PM group (37.8% vs 28.2%) (p=0.02). Patients with PM had a significantly greater interval from primary diagnosis to the date of first systemic treatment as compared to those without (median: 44 vs 5 months) (p<0.001). As expected, patients with PM in the overall population had improved OS from the primary diagnosis compared to non-PM [70 vs 28 months (HR 0.51, p<0.01)]. Similarly, PFS from diagnosis was significantly prolonged in those with PM (68 vs 19 months, HR 0.44, p<0.01). Importantly patients who have PM who receive either single agent TKI or IO/TKI have a significant improvement in survival compared to those without PM. The same significant improvement is not seen in PM patients who receive IO/IO combinations first line. Conclusions: As predicted based upon previous publications, our study demonstrated that patients with PM from RCC have relatively longer survival times than patients with metastatic RCC of other sites. More importantly though for decision making, patients who receive TKI based treatment have an improvement in outcome in patients with PM compared to treatments that do not contain a TKI. This would advocate TKI monotherapy or IO/TKI regimens in this patient group. Clinical trial information: (REC reference 24/SC/0038) IRAS project ID 338935 .
Real-world treatment patterns and outcomes of novel androgen receptor axis-targeted agents in non-metastatic castration-resistant prostate cancer: A multi-institutional retrospective study.
368 Background: Recently, three phase III trials have demonstrated that novel androgen receptor axis-targeted agents (ARATs) significantly improved metastasis-free survival (MFS) and overall survival (OS) compared to placebo in patients with non-metastatic castration-resistant prostate cancer (nmCRPC). However, the treatment patterns and outcomes of novel ARATs in real-world settings remain unclear. Methods: This multi-institutional retrospective study included 245 patients with nmCRPC treated between September 2003 and April 2024. Trends in the use of novel ARATs were evaluated. Patients were divided into two groups: those who were treated with any novel ARATs, including apalutamide, enzalutamide, darolutamide, and abiraterone acetate, during any line of nmCRPC treatment (novel ARATs group) and those who were not (control group). Multivariable Cox proportional hazards regression analyses were performed to evaluate the effects of novel ARATs on MFS and OS. Adverse events (AEs) associated with novel ARATs were evaluated using the Common Terminology Criteria for Adverse Events version 5.0. Results: The median age and follow-up period after nmCRPC diagnosis were 77 years and 45 months, respectively. Of the 245 patients, 175 (71%) were treated with novel ARATs after nmCRPC diagnosis. Novel ARATs use in first line and any line was gradually increased from 2014 to 2023 (0% to 85% and 38% to 92%, respectively). The MFS and OS in the novel ARATs group were significantly longer than those in the control group ( P < 0.001 and P = 0.001, respectively). In multivariable analyses, a prostate-specific antigen doubling time (PSADT) and novel ARATs were independently and significantly associated with MFS and OS (Table). The rate of grade 3 AEs and discontinuation due to AEs were 1.1% and 6.0%, respectively. Conclusions: The use of novel ARATs for the treatment of nmCRPC increased over time. Novel ARATs use was safe and associated with improved oncological outcomes in a real-world setting. Multivariable analyses for MFS and OS. MFS Factor P value Hazard ratio 95% CI Age Continuous 0.003 0.956 0.928–0.984 Time of nmCRPC diagnosis Before 2014 0.706 0.917 0.584–1.439 PSADT <2.5 months <0.001 2.040 1.339–3.107 Novel ARATs Positive <0.001 0.364 0.238–0.557 OS Factor P value Hazard ratio 95% CI Age Continuous 0.418 1.014 0.980–1.049 Time of nmCRPC diagnosis Before 2014 0.626 0.883 0.537–1.454 PSADT <2.5 months <0.001 2.138 1.360–3.360 Novel ARATs Positive 0.001 0.479 0.306–0.748
Lutetium-177 PSMA radioligand therapy in taxan-naive first- and second-line metastatic castration resistant prostate cancer after first-line ARPI therapy.
79 Background: Lutetium-177 Prostate-specific membrane antigen (Lu-PSMA) radioligand therapy is EMA-approved for metastatic castration resistant prostate cancer (mCRPC) after androgen receptor pathway inhibition (ARPI) and taxane-based chemotherapy. However, its effect in taxane-naïve patients is under current investigation. Methods: We relied on the FRAMCAP database to elaborate Lu-PSMA therapy outcomes of progression-free (PFS) and overall (OS) in taxane-naïve mCRPC patients after previous ARPI treatment. Comparison was made against current standard of care with ARPI or docetaxel. Results: Of 269 patients, 11% received Lu-PSMA in first/second-line mCRPC vs. 57% ARPI vs. 33% docetaxel. Mostly no significant baseline differences between Lu-PSMA and ARPI patients were observed, while Lu-PSMA patients were significantly older, received less systematic treatments and ECOG1-2 proportions were higher, relative to docetaxel patients. In PFS (13.3 vs. 8.2 months, hazard ratio [HR]: 0.70, p=0.16) and OS analyses (68.9 vs. 39.1 months, HR: 0.64, p=0.2), Lu-PSMA was numerically more favorable than ARPI. In additional multivariable Cox regression models, Lu-PSMA was significant better regarding PFS and OS, relative to ARPI (both p<0.05). Compared to docetaxel, also significant better PFS (13.3 vs. 8.1 months, HR: 0.46) and OS (68.9 vs. 27.3 months, HR: 0.34, both p<0.01) was observed for Lu-PSMA treatment. The OS advantage was also observed after multivariable adjustment (p<0.01). Conclusions: Real-world evidence suggests that Lu-PSMA therapy provides significantly better PFS and OS outcomes in taxane-naïve mCRPC patients after previous ARPI treatment, relative to ARPI or docetaxel treatment and should therefore considered as an early mCRPC treatment. A B Characteristic N Overall N = 269 1 Lu-PSMA, N = 29 (11%) 1 ARPI, N = 152 (57%) 1 p-value 2 Docetaxel, N = 88 (33%) 1 p-value 2 Age at metastatic disease, years 256 71 (65, 77) 74 (69, 79) 72 (66, 77) 0.055 68 (62, 73) <0.001 Age at mCRPC, years 167 72 (67, 79) 76 (73, 83) 74 (68, 79) 0.083 69 (64, 75) <0.001 PSA at mCRPC, ng/ml 133 17 (6, 47) 23 (9, 82) 18 (5, 47) 0.2 12 (4, 40) 0.091 Systemic treatment lines for mCRPC 269 3 (2, 4) 2 (1, 2) 3 (2, 4) <0.001 3 (3, 5) <0.001 Received cycles 139 3 (2, 6) 3 (2, 5) 4 (2, 6) 0.2 PSA response, % 26 23 (4, 62) 20 (11, 30) 17 (0, 90) 0.9 41 (17, 62) 0.3 ECOG at mCRPC 87 0.13 0.017 0 40 (46%) 4 (24%) 17 (45%) 19 (59%) 1-2 47 (54%) 13 (76%) 21 (55%) 13 (41%) Cardiovascular disease 171 64 (37%) 9 (50%) 33 (34%) 0.2 22 (39%) 0.4 Gleason score 8-10 234 165 (71%) 16 (62%) 89 (69%) 0.5 60 (76%) 0.2 Local therapy 269 112 (42%) 12 (41%) 52 (34%) 0.5 48 (55%) 0.2 De Novo metastatic disease 259 140 (54%) 15 (54%) 86 (59%) 0.6 39 (45%) 0.4 High volume mHSPC 104 55 (53%) 6 (67%) 35 (54%) 0.7 14 (47%) 0.5 Metastatic sites at mCRPC 110 0.8 0.4 M1a 13 (12%) 2 (11%) 5 (10%) 6 (15%) M1b 91 (83%) 15 (79%) 42 (84%) 34 (83%) M1c 6 (5.5%) 2 (11%) 3 (6.0%) 1 (2.4%)
Fifteen-year outcomes of external radiation with or without 6 months of neoadjuvant deprivation therapy for intermediate risk prostate cancer.
388 Background: Our aim is to retrospectively compare survival outcomes in intermediate-risk prostate cancer (IRPC) treated with external-beam radiation therapy (EBRT) with or without neoadjuvant-deprivation-therapy (NADT). Methods: Retrospective analysis was performed on 566 IRPC treated with EBRT from 2004-2007. NADT was given to 336 patients, while 230 underwent EBRT alone. Median duration of NADT was 6 months. Median dose of radiation was 75.6 Gy to isocenter. Freedom-from-biochemical-failure (FFBF) was defined by the PSA nadir+2.0. Multi-variable analysis and Kaplan-Meier estimates were performed. Results: Median follow-up was 11.5 years in the NADT+EBRT vs 12.0 years in the EBRT alone group, with up to 19.8 years of follow-up. NADT+EBRT had more adverse factors of clinical stage (p=0.02), iPSA (p<0.01), Gleason group (p=0.02), %cores>50% (p<0.01). 15-year FFBF, metastases-free-survival (MFS), prostate-cancer-specific-survival (PCSS), and overall survival (OS) for NADT+EBRT vs EBRT alone was 52% vs 49% (p=0.41), 85% vs 83% (p=0.59), 91% vs 91% (p=0.67), 53% vs 51% (p=0.82). Conclusions: After 15 years of follow-up, IRPC treated with EBRT with or without 6 months of NADT experienced a high PCSS of 91%, despite a very high PSA failure rate of about 49-52% of the patients. It’s unclear if 6 months NADT in addition to EBRT can improve PCSS or overall survival for IRPC, or just merely delay PSA progression.
Fair food futures UK: Protocol for a mixed methods study exploring what approaches adopted by community food organisations are more likely to prevent the need for emergency food in two multicultural communities in Northern and Southern England
Introduction Food insecurity reduces people’s chances to live healthy and active lives and places a significant burden on healthcare systems. Levels have significantly increased in the UK since 2010, due to the impact of austerity and, more recently, the COVID-19 pandemic and the cost of living crisis. This increase is projected to continue. Households with children are amongst those at highest risk for food insecurity. A variety of community food organisations (CFOs), such as community gardens, community kitchens, food banks and social markets, have been essential in responding to rising food insecurity, including providing emergency food and other types of support such as welfare advice. However, beyond food banks, little is known about differing approaches to food aid in the UK, including how these organisations provide additional services to address the underlying issue that has led someone to seek emergency food support. Aim To understand what approaches used by community food organisations are most likely to help prevent the need for emergency food in two multicultural communities in the North (Bradford) and South (Tower Hamlets, London) of England, with high levels of ill-health and food insecurity. Research design, setting and participants This is a mixed methods study informed by complex systems theory. Methods include participatory systems mapping and qualitative longitudinal research. We will map the availability and type of help with food, and produce a typology of CFO approaches, using a survey, multiple local and national participatory system mapping workshops and interviews with local and national stakeholders (WP1). Then, we will conduct a longitudinal qualitative research using a ‘researcher in residence’ approach in up to 10 CFOs purposively sampled to reflect the diversity of prevention strategies adopted by CFOs. Research will include: a) a 12 month ethnographic study; b) three waves of ‘go along’ interviews with up to 35 families; and c) a visual study where the same families are invited to share photos and videos about their food thoughts via Indeemo research app. Outputs and dissemination Outputs will include: a) a toolkit on CFOs to support local and national policy and implementation decisions, b) a travelling exhibition with visual representations of people’s lived experiences c) publications in academic journals, d) blog posts, e) public talks, and f) policy briefs. Findings will help decision makers to invest in the most accessible, beneficial and culturally appropriate resources for communities.
Two-stream spatio-temporal GCN-transformer networks for skeleton-based action recognition
Detection of early-stage urothelial cancers using methylation patterns in urine cell-free DNA.
687 Background: Urine cell-free DNA (ucfDNA) has the potential to improve detection and monitoring of early-stage urothelial carcinoma (UC). We previously demonstrated the utility of ucfDNA methylation patterns to detect non-muscle invasive bladder cancer (NMIBC) in patients with suspicious bladder lesions (by cystoscopy or imaging). Based on those results, we trained a biopsy-free urine classifier for cancer detection. Here, we evaluate the performance of the urine classifier in an independent test set of patients with early-stage NMIBC or upper tract UC (UTUC). Methods: The urine classifier was trained using GRAIL’s biobank of plasma and cancer tissue, as well as prospectively collected urine from cancer and non-cancer participants (urine samples, n = 468). The locked classifier was evaluated at 95% and 98% target specificities on an independent test set of biobanked urine from patients with a new diagnosis of NMIBC (n = 49, 24 low grade and 25 high grade) and UTUC (n = 19, 9 low grade and 10 high grade), as well as age- and gender-matched non-cancer controls (n = 66). Results: The observed specificities in the test set at target specificities of 95% and 98% were 93.9% (62/66, 95% CI 85.2-98.3%) and 97.0% (64/66, 95% CI 89.5-99.6%), respectively. Observed sensitivity was the same at both target specificities. Of the 68 patients with a new diagnosis of either NMIBC or UTUC, 57 were classified as cancer, while 11 were classified as non-cancer. The urine classifier had a sensitivity of 100% for high grade NMIBC (25/25; 95% CI 86.3-100%) and 58.3% for low grade NMIBC (14/24; 95% CI 36.6-77.9%). For patients with UTUC, the urine classifier had a sensitivity of 100% for high grade UTUC (10/10; 95% CI 69.2-100%) and 88.9% for low grade UTUC (8/9; 95% CI 51.8-99.7%). Conclusions: A biopsy-free urine classifier based on ucfDNA methylation patterns is able to identify early-stage NMIBC and UTUC with high sensitivity at high specificity, particularly for patients with high grade disease. The classifier performance was validated in urine with an independent test set and did not require matched blood or tissue, highlighting the potential for a non-invasive and cost-effective method for UC screening. Current efforts are focused on evaluating urine classifier performance in prospective cohorts of UC patients undergoing both screening and recurrence monitoring.
Characterizing the clinical and genomic features of androgen indifferent prostate cancer.
222 Background: Androgen indifferent prostate cancer (AIPC) is increasingly common and particularly lethal. Data describing these tumors are sparse and AIPC remains a poorly understood malignancy. This study aims to characterize the clinical and genomic features of AIPC. Our work ultimately seeks to identify biomarkers with diagnostic and therapeutic potential. Methods: Utilizing the Oncology Research Information Exchange Network (ORIEN) database, we queried all prostate cancer (PC) patients, identified metastatic castrate resistant prostate cancer (MCRPC) samples, and aimed to enrich for tumors with features of AIPC using previously described characteristics. Our AIPC cohort included three subgroups: aggressive variant prostate cancer (AVPC) defined as having alterations in at least two of TP53, RB1, PTEN; neuroendocrine PC (NEPC) defined as small cell histology or NEPC signature score ≥ 0.25 (1); and double-negative PC (DNPC), defined as non-NEPC patients with low AR expression/AR signaling score. We compared clinical characteristics and genomic analysis of AIPC vs non-AIPC samples in patients who developed MCRPC. Clinical analysis was done using Wilcoxon rank sum test or Fisher's exact test. Gene expression analysis was performed using DESeq2 and GSEA. Results: Of 1,496 total PC patients available for analysis, we identified 323 (22%) as MCRPC. Of those, 39 (12%) met AIPC criteria (17 AVPC, 13 NEPC, 9 DNPC) and 284 (88%) were non-AIPC. Median age at diagnosis for AIPC was 62 years and 85% were white, compared to 62 years and 87% for non-AIPC. Fifty-seven percent of AIPC patients had ECOG ≥1 at diagnosis vs 16% of non-AIPC. Forty-three percent of AIPC patients had de novo metastatic disease vs 15% for non-AIPC (p=0.003). TMPRSS2-ERG gene fusions were found in a significantly higher proportion of AIPC samples vs non-AIPC (38.5% vs 16%, p=0.014). Homologous recombination deficiency (HRD) and tumor mutational burden (TMB) did not differ between cohorts, but microsatellite instability scores (MSI) were significantly higher in AIPC (p=0.019). Using Gene Set Enrichment Analysis (GSEA), we found that genes defining response to androgens and genes involved in oxidative phosphorylation were the most downregulated, whereas genes involved in epithelial mesenchymal transition (EMT), interferon response, and angiogenesis were significantly upregulated in AIPC vs non-AIPC samples. Conclusions: There was a significantly higher rate of de novo metastasis in the AIPC cohort. The downregulated androgen response and upregulated EMT pathways in AIPC suggest enrichment for androgen indifference with our methodology. Upregulated immune signaling and angiogenesis as well as higher MSI suggest opportunities for therapeutic investigation. Future directions include more focused in vitro and in vivo analysis to identify actionable targets. 1. Beltran H, et al. Nat Med . 2016;22(3):298-305. doi:10.1038/nm.4045.
Baseline fracture risk for prostate cancer patients initiating long-term androgen deprivation therapy.
122 Background: Androgen deprivation therapy (ADT) is essential for management of advanced prostate cancer, yet it carries risks including osteoporosis and fragility fractures. Antiresorptive therapy is recommended to reduce fractures for patients at high risk. However, precisely which patients should undergo formal screening with dual-energy X-ray absorptiometry (DEXA) at baseline has been relatively unexplored. This study aims to describe these baseline fracture risks, the utility of DEXA screening based upon Fracture Risk Assessment Tool (FRAX) scores, and the impact of specific risk factors in this population. Methods: We performed a retrospective cross-sectional study of patients at our institution with prostate cancer treated with ≥1 year of ADT between 2011 and 2024. Patients were excluded if their FRAX scores were incalculable or if they received antiresorptive therapy prior to starting ADT. Ten-year hip and combined major osteoporotic fracture risks were calculated using FRAX without femoral neck T-scores for all patients and with femoral neck T-scores for patients who received DEXA scans. A high fracture risk was defined as a 10-year hip fracture ≥3% or a combined major osteoporotic fracture risk ≥20%. Differences between dichotomous groups were assessed using independent samples t-tests, Chi-square tests, or Fisher’s exact tests. Results: We identified 515 patients with an average age of 70.1 years and average BMI of 29.5 kg/m 2 . Four hundred and forty-eight (87%) patients received leuprolide as ADT, 70 (13.6%) patients were on a prednisone-containing regimen, and 66 (12.8%) patients were active smokers. Based upon clinical data at ADT initiation (without including T-scores from DEXA), 201 (39.0%) patients had a high 10-year risk of hip or combined major osteoporotic fracture by FRAX. Among the 183 patients who did have DEXA scans, 85 (46.4%) met criteria for osteopenia while 14 (7.7%) had osteoporosis by T-score. Additionally, 48 (26.2%) patients had high 10-year fracture risks by FRAX and met criteria for initiation of antiresorptive therapy. The patients meeting criteria for antiresorptive therapy, in general, were older (73.3 years vs. 67.9 years) and weighed less (87.8 kilograms vs. 96.3 kilograms). Conclusions: In our institutional experience, nearly half of patients starting long term ADT have significant fracture risk warranting further risk stratification and risk mitigation strategies. This baseline data should inform systematic approaches to select those that do—and do not—require bisphosphonate or denosumab in the hormone sensitive setting.
Updated long-term follow-up from a phase II clinical trial of gemcitabine and cisplatin as neoadjuvant chemotherapy for patients with high-grade upper tract urothelial carcinoma.
811 Background: We previously reported our multicenter phase II trial of neoadjuvant gemcitabine and split-dose cisplatin (GC) in 57 patients with high-grade upper tract urothelial carcinoma (HG UTUC), where 63% of patients experienced a pathological response (<ypT2 N0) at radical nephroureterectomy (RNU). Pathological response was associated with superior progression-free (PFS) and overall survival (OS) over a median 3-years of follow-up. Herein we report survival outcomes among the 50 patients treated at our institution with long-term follow-up. Methods: Patients with histologically confirmed HG UTUC and/or radiographically visible tumor stage T2-T4a N0/NX disease with a positive upper tract urine cytology were eligible. All patients received 4 cycles of split-dose GC followed by RNU and lymphadenectomy. The primary endpoints for this report were PFS (defined as metastasis or death from UTUC), cancer-specific survival (CSS) and OS, stratified by pathological response to NAC. Responders (<ypT2 N0) included both complete responders (CR, ypT0 N0) and partial responders (PR, ypTa/Tis/T1 N0/X); non-responders (NR) included ≥ypT2 Nany. Follow up started at RNU and patients were censored at the last occurrence of: clinical assessment, imaging study, or blood draw. Kaplan-Meier analyses estimated survival outcomes and log-rank tests evaluated for significant differences. Results: Of the 50 patients available for analysis, 32 (64%) were responders, of which 10 (20%) were CR. Baseline characteristics were similar between responders and NR. Forty-four of 50 patients tolerated ≥3 cycles of GC. Over a median follow-up among survivors of 5.7 years (interquartile range: 5.0, 7.9), 16 progression events, 11 cancer-specific deaths, and 16 total deaths occurred. Overall event rates were 63% and 63% for PFS, 77% and 70% for CSS, and 75% and 54% for OS, at 7- and 9-years, respectively. Estimated survival was higher among responders, compared to NR for PFS (log-rank p<0.001), CSS (log-rank p=0.002), and OS (log-rank p=0.002); corresponding 7- and 9-year event rates are presented in the table. Survival and event estimates were similar between CR and PR. Conclusions: These findings demonstrate a durable long-term progression and survival advantage of split-dose GC as NAC for HG UTUC among patients with a pathological response. Clinical trial information: NCT01261728 . 7- and 9-year PFS, CSS, and OS rates in patients treated with NAC, stratified by pathological response at RNU. Outcome Characteristic* 7 Years (95% CI) 9 Years (95% CI) PFS Responders 80% (64%, 99%) 80% (64%, 99%) Non-responders 36% (19%, 69%) 36% (19%, 69%) CSS Responders 89% (76%, 100%) 79% (60%, 100%) Non-responders 54% (33%, 88%) 54% (33%, 88%) OS Responders 87% (73%, 100%) 67% (46%, 99%) Non-responders 54% (33%, 88%) 32% (14%, 77%) *Responders were defined as <ypT2 N0/NX; Non-responders were defined as ≥ypT2 Nany.
The impact of Duration of Untreated Psychosis on functioning and quality of life over one year of Coordinated Specialty Care (CSC)
Background This study examined the relationship between the Duration of Untreated Psychosis (DUP) and functional outcomes at baseline, 6 months, and 12 months after admission to Coordinated Specialty Care (CSC). Methods A total of 246 participants from two U.S. public-sector CSC programs were categorized into Low and High DUP groups using two criteria: (i) a median split of the DUP distribution and (ii) the World Health Organization (WHO) aspirational standard of 3 months. Changes in global functioning (GAF), social functioning (GF: Social), and occupational functioning (GF: Role), symptom severity (PANSS), and quality of life (QoL) were assessed using a Linear Mixed Model Repeated Measures (MMRM) analysis across the three time points. A Generalized Linear Model (GLM) with a logit link function was applied to analyze binary outcomes, specifically the status of being Neither in the Labor Force, Education, or Training (NLFET). Both models adjusted for time and site as covariates and used an unstructured variance-covariance matrix to account for within-subject correlations in repeated measures. The difference-in-differences method was employed to estimate the impact of DUP on outcomes over time, with results reported as least square means for continuous outcomes, odds ratios for binary outcomes, and 95% confidence intervals (CI) for both Low and High DUP groups. Results No significant differences were observed between the Low and High DUP groups at baseline. By 6 months, participants in the Low DUP group (DUP < 3 months) exhibited significantly greater improvements (reduction) in NLFET status (3-month OR = 3.25, p = 0.03; median split OR = 2.25, p = 0.03) and global functioning, GF: Role, and GF: Social. By 12 months, the Low DUP group continued to show significantly greater NLFET status improvement (3-month OR = 3.59, p = 0.03; median split OR = 3.40, p = 0.0032). Improvements in global functioning were sustained at 12 months, while social and occupational functioning gains were not. No significant differences were observed between groups for quality of life or symptom severity over time. Conclusion Shorter DUP is linked to more rapid functional recovery within the first year after CSC admission.
Research on the properties of polymer stabilized coal gangue materials in rubber powder slag base
Comprehensive bladder cancer molecular profiling and monitoring based on mutational, epigenomic, and expression data from real-world patients.
860 Background: Bladder cancer poses considerable therapeutic challenges, particularly in the context of bladder preservation strategies that aim to balance maintaining quality of life with achieving optimal survival outcomes. Traditional treatments, such as radical cystectomy, often have profound impact on patient morbidity. However, recent advances in molecular profiling -- including mutational, epigenomic, and gene expression analyses -- offer promising avenues for personalized cancer treatment approaches. Despite these advances, comprehensive studies leveraging detailed analysis of molecular profiling and urine-based monitoring in bladder cancer are lacking. Methods: A cohort of 30 real-world patients with bladder and upper tract urothelial carcinoma (UTUC) of various subtypes were included in this study. Standard treatment modalities employed were neoadjuvant chemotherapy, trimodality therapy (TMT) for bladder preservation, and systemic chemotherapy or immunotherapy in the metastatic setting. PredicineCOMPLETE is an integrated assay that interrogates genomic alterations such as mutations, copy number variations (CNVs), and gene fusions – as well as DNA methylation and transcriptomic profiles. All samples had previously undergone the PredicineBEACON urine MRD test, which covers mutation/CNV/fusion analysis. We further performed whole-transcriptome sequencing (WTS) on baseline urine cell pellet (UCP) samples, and the PredicineEPIC DNA methylation assay on all the follow-up timepoint samples. Results: The PredicineCOMPLETE assay generated significantly more comprehensive data compared to mutational panels alone, providing a rich molecular landscape of each patient’s tumor biology. Comprehensive correlation analysis between DNA methylation and RNA expression were conducted. Strong correlation was observed for some bladder cancer biomarker genes such as TERT and TP53. An AI model was trained using patients’ treatment decision (bladder preservation versus surgery), clinical features, and the comprehensive molecular data obtained. The trained AI model accurately matches the physician’s choices over 90% of the validation cases. Conclusions: This study demonstrates that comprehensive molecular profiling using the PredicineCOMPLETE assay helps us understand the underlying disease biology. Combined with machine learning and AI modeling, it can effectively assist in treatment decision-making for bladder cancer patients. While these initial results are encouraging, the limited sample size necessitates further validation in larger, independent cohorts to confirm the model’s efficacy and generalizability.
Non-muscle invasive bladder cancer treatment selection in an emerging treatment era: A patient preference study.
754 Background: Patients with non-muscle invasive bladder cancer (NMIBC) who become unresponsive to Bacillus Calmette-Guérin (BCG) face preference-sensitive choices between emerging and established bladder-sparing treatments or radical cystectomy (RC). This study elicited 1) the preferences of patients in the United States for bladder-sparing treatments with different benefits and burdens and 2) their choice between these options and RC. Methods: Patients with self-reported NMIBC and BCG experience completed an online survey. A discrete-choice experiment (DCE) elicited preferences for hypothetical bladder-sparing treatments. Evidence-based treatment attributes (and levels) included chance of recurrence of NMIBC (45%-69%) and chance of progression to MIBC 1 year after treatment (2%-30%); administration burden (intravesical every week depending on response or every 3 months for 1 year, or intravenous every 6 weeks for up to 2 years); treatment-related fatigue (none to moderate-severe); chance of discomfort and pain or urinary tract infection (0%-30%); and chance of developing immune-related adverse events (AEs) (0%-25%). Conditional relative importance of attributes and risk tolerance measures were calculated from random parameter logit models. In addition to the DCE, direct-elicitation questions offered choices between fixed profiles of different bladder-sparing treatments and RC. The Shared Decision Making (SDM) Questionnaire (SDM-Q-9) revealed patients’ levels of satisfaction with previous real-world choices. Responses to the fixed-profile questions and SDM-Q-9 were analyzed descriptively. Results: Among the 206 respondents, reduced risks of progression and disease recurrence were the most important attributes given the range of levels included in the DCE. The other attributes—treatment-related AEs and administration burden—were less important and had statistically similar impacts on choices. On average, patients were willing to accept a >25% risk of immune-related side effects requiring oral steroids to achieve the greatest reductions in disease progression and recurrence offered in the survey. With the exception of repeated BCG-like therapy, most patients (>70%) preferred bladder-sparing treatments over RC. Over 25% of respondents disagreed with the statement “My doctor asked me which treatment option I prefer” when reflecting on their SDM experiences. Conclusions: Patients with NMIBC cared most about treatment efficacy and were generally willing to accept clinically relevant levels of treatment-related risks and discomfort to achieve reductions in disease progression and recurrence. Patients demonstrate heterogeneous preferences, and continued efforts to incorporate shared decision-making into treatment decisions are warranted.
Pilot study evaluating duplex sequencing of urinary DNA as a biomarker for recurrence in non-muscle invasive bladder cancer.
865 Background: The detection of tumor-associated urinary DNA (uDNA) as a biomarker for non-muscle invasive bladder cancer (NMIBC) has shown promise, but is significantly limited in sensitivity due to replication errors inherent in next-generation sequencing (NGS). Duplex sequencing is an ultrasensitive/accurate sequencing technology which may provide a solution to this problem. We present a pilot study applying duplex sequencing technique to uDNA in NMIBC for use as a biomarker of recurrence. Methods: Urine samples from a total of 30 patients with NMIBC were collected following complete transurethral resection of bladder tumor and prior to intravesical therapy (pre-tx) and following six weeks of intravesical therapy (post-tx). Detection of ten commonly mutated NMIBC genes was carried out using next generation duplex sequencing. Results were correlated with recurrence of tumor. Results: Median age for our cohort was 71 [41, 88] and 80% were male. A total of 16 (53.3%) of the cohort experienced a recurrence within the first year, with a median time to recurrence of 10 months. Tumor-associated uDNA was successfully detected to variant allele fraction (VAF) below 0.001. Presence of any pathogenic variant in the pre-tx urine >0.006 VAF was associated with a 72.7% sensitivity and 78.9% specificity for recurrence within one year. The highest VAF of pathogenic variant in uDNA trended with time-to-relapse. Post-tx uDNA assessment did not correlate with recurrence. Further analysis is limited by small sample size. Conclusions: This pilot study demonstrates potential utility of ultrasensitive duplex sequencing on NMIBC uDNA in the detection of recurrence.
Developing a deep learning algorithm for automated p53 immunohistochemistry digital image analysis in prostate cancer.
223 Background: p53 immunohistochemistry (IHC) is a prognostic marker in prostate cancer (PCa), but manual scoring by pathologists is time-consuming and prone to variation. Digital image analysis (DIA) offers a potential solution to enhance speed, accuracy, and reproducibility. This study aims to develop a DIA algorithm for scoring p53 IHC in PCa and compare its performance with manual scoring. Methods: Forty patients with adequate archival PCa tissue were randomly selected, and representative sections were stained for p53 IHC. Two pathologists independently scored p53 nuclear expression based on intensity (0, 1+, 2+, 3+) and percentage of expression in tumor cells (0%, < 1%, 1–5%, > 5%). Whole slide images (WSIs) were analyzed using a Visiopharm batch processing workflow. In a training set of 14 samples, each WSI was manually segmented into benign, tumor, and background regions. The algorithm with the highest accuracy for tumor detection was selected for p53 scoring. Artifacts generating false positives, such as surgical ink and pigments, were filtered by an Artifact Detection APP. Problematic segmentation issues, including hemosiderin-laden macrophages and folded tissue sections, were manually excluded. A Tumor Detection APP identified tumor regions of interest. A Nuclei Detection APP identified the tumor nuclei and was calibrated to differentiate 3,3′-diaminobenzidine (DAB) intensity thresholds for scores of 0–3+ on the evaluation set of 40 samples. The final application was applied to the evaluation set, and results were compared with manual pathologist scores. All image analysis algorithms were trained using convolutional neural networks (CNNs) on pathologist-guided training sets within the Visiopharm platform, executed as part of the whole slide analysis protocol. Results: Comparison of automated DIA p53 scores with manual consensus scores (Table) revealed a Kendall’s coefficient of concordance of 0.81 (p = 0.008), indicating strong agreement. The Goodman-Kruskal Gamma coefficient showed a high correlation of 0.8 (95% CI: 0.6-1.0). The estimated Volume Under the ROC Surface (VUS) for the 4-level ordinal score was 0.68 (SE = 0.11), suggesting moderate to high discriminatory power in distinguishing among the four scoring levels based on the percentage of positive nuclei. Conclusions: The strong inter-rater agreement and high correlation between manual and DIA scores suggest that the deep learning algorithm assesses p53 IHC in PCa with moderate to high discriminatory power. Robust slide selection is crucial to minimize false positives. These findings highlight the potential of automated DIA to enhance efficiency and standardization of p53 IHC scoring. Distribution of manual p53 scores (rows) and automated digital image analysis (DIA) p53 scores (columns) by intensity. Manual p53 scores (n) Automated DIA p53 scores (n) 0 1+ 2+ 3+ 0 18 5 1 2 1+ 1 5 3 1 2+ 0 0 2 0 3+ 0 0 0 2
Prevalence and associated factors of diabetic ketoacidosis among patients with diabetes mellitus at the University of Gondar Comprehensive and Specialized Referral Hospital Northwest, Ethiopia
Background Diabetes is a group of metabolic diseases characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both. Diabetic ketoacidosis is one of the life-threatening complications in diabetic individuals with, high morbidity and mortality globally. However, the data related to the prevalence and associated factors of diabetic ketoacidosis are limited in the study setting. Objective To assess the prevalence of diabetic ketoacidosis and its associated factors among diabetic mellitus patients at the University of Gondar Comprehensive Specialized Hospital. Methods A hospital-based cross-sectional study was conducted from March 1 to September 30, 2021. A total of 405 diabetic patients aged 20 and above were selected using a systematic random sampling technique. A total of 810 blood and urine samples (each 405) were collected using sterile serum separator tubes and urine collection cups, respectively. Sociodemographic and clinical data was collected using a structured questionnaire. Chemical analysis of urine was done using urine reagent strips to determine urine ketone bodies and PH. BECKMAN COULTER DxC700 AU clinical chemistry analyzer instrument was used to determine electrolytes and metabolites. The data was entered using Epi-Data version 4.6 and transferred to SPSS version 25 for analysis. Bivariable and multivariable logistic regression analyses were used to determine the factors associated with the diabetic ketoacidosis. The results were considered statistically significant if the adjusted odds ratio was reported with a 95% confidence interval and a P-value below 0.05. Results The overall prevalence of diabetic ketoacidosis among diabetic patients was 35/405 (8.6%, 95% CI: 6.0–11.0%). Of these cases, 25 (71.4%) had type 1 diabetes mellitus, while 10 (28.6%) had type 2 diabetes mellitus. Statistically significant factors associated with diabetic ketoacidosis included being a young adult aged 20–29 years (AOR = 2.262; 95% CI = 1.090–4.758; P = 0.013), unemployment (AOR = 2.578; 95% CI = 1.457–6.113; P = 0.017), the presence of infection (AOR = 2.819; 95% CI = 1.138–8.428; P = 0.024), and being T1DM (AOR = 3.106; 95% CI = 1.150–7.273; P = 0.003). Conclusions and recommendations The prevalence of diabetic ketoacidosis among follow-up diabetes patients in this study was high, particularly among those aged 20–29 years, unemployed, or with infections. Increased vigilance, regular monitoring, timely infection management, and comprehensive diabetes education are essential for early detection and prevention of DKA. Social and financial support for unemployed diabetic patients can further enhance access to care and reduce DKA risk.